Comparative Pharmacology
Head-to-head clinical analysis: CECLOR versus SPECTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR versus SPECTRACEF.
CECLOR vs SPECTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It exhibits bactericidal activity against susceptible organisms.
Cefditoren, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
250 mg orally every 8 hours; for severe infections, 500 mg orally every 8 hours.
400 mg orally twice daily for 10-14 days.
None Documented
None Documented
Terminal elimination half-life: 0.6-0.9 hours in adults with normal renal function. Prolonged to 2-3 hours in end-stage renal disease. Half-life does not increase significantly with hepatic impairment.
Terminal elimination half-life: 2.5 hours (range 2.0-3.0 hours) in healthy adults; prolonged in renal impairment (up to 10 hours in severe impairment)
Primarily renal: 80-90% of unchanged drug excreted by glomerular filtration and tubular secretion within 8 hours. Biliary excretion accounts for <5%; fecal elimination negligible.
Renal: 88% as unchanged drug, Fecal: negligible, Biliary: minimal
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic